Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis

OBJECTIVE: With a vaccine effectiveness of 95% for preventing coronavirus disease 2019 (COVID‐19), Pfizer‐BioNTech BNT162b2 (BNT162b2) was the first vaccine against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) to be approved. However, immunosuppressive therapy was an exclusion criter...

Descripción completa

Detalles Bibliográficos
Autores principales: Ammitzbøll, Christian, Bartels, Lars Erik, Bøgh Andersen, Jakob, Risbøl Vils, Signe, Elbæk Mistegård, Clara, Dahl Johannsen, Anders, From Hermansen, Marie‐Louise, Kragh Thomsen, Marianne, Erikstrup, Christian, Hauge, Ellen‐Margrethe, Troldborg, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426741/
https://www.ncbi.nlm.nih.gov/pubmed/34273260
http://dx.doi.org/10.1002/acr2.11299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426741/
https://www.ncbi.nlm.nih.gov/pubmed/34273260
http://dx.doi.org/10.1002/acr2.11299

Ejemplares similares